⁸⁹Zr-PET imaging to predict tumor uptake of ¹⁷⁷Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma.

ABSTRACT: [¹⁷⁷Lu]Lu-DOTA-NNV003, a radioimmunoconjugate targeting CD37, is developed as novel radioimmunotherapy (RIT) treatment for patients with B cell non-Hodgkin's lymphoma (NHL). Since patients are at risk for developing hematological toxicities due to CD37 expression on normal B cells, we aimed to develop ⁸⁹Zr-labeled NNV003 for positron emission tomography (PET) imaging as a surrogate tool to predict [¹⁷⁷Lu]Lu-DOTA-NNV003 RIT whole-body distribution and tumor uptake. NNV003 antibody was first radiolabeled with ⁸⁹Zr. [⁸⁹Zr]Zr-N-sucDf-NNV003 tumor uptake was evaluated by PET imaging of mice bearing human CD37-expressing REC1 B cell NHL or RAMOS Burkitt's lymphoma xenograft tumors followed by ex vivo analysis. Finally, CD37-targeting of [

SUBMITTER: Giesen D 

PROVIDER: S-EPMC9012778 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature